Pinealon, also known as Ala-Glu-Asp or EDR tripeptide, is a synthetic peptide composed of three amino acids: alanine, glutamic acid, and aspartic acid. It is categorized as a nootropic compound, primarily investigated for its potential effects on the central nervous system (CNS). Pinealon is synthesized through standard peptide synthesis techniques, which involve the sequential addition of protected amino acids to form the desired tripeptide structure. Researchers have shown interest in Pinealon due to its potential neuroprotective and cognitive-enhancing properties. Studies have explored its effects on memory, learning, and overall brain function. Pinealon has been observed to exhibit antioxidant properties, which may contribute to its neuroprotective effects. Additionally, it has been investigated for its potential role in reducing oxidative stress and modulating neuronal activity. The mechanism of action of Pinealon is not fully understood, but it is believed to interact with cellular pathways involved in oxidative stress and apoptosis. Researchers have suggested that Pinealon may influence the expression of genes related to cell survival and neuroprotection. Its effects on mitochondrial function and cellular energy metabolism have also been subjects of investigation. Pharmacokinetic data on Pinealon is limited. Researchers have noted that its stability and bioavailability can vary depending on the route of administration. The half-life of Pinealon is not well-documented, and further studies are needed to elucidate its pharmacokinetic profile. Currently, Pinealon is primarily a subject of preclinical research, with limited clinical trials conducted. It is not approved as a medicinal product in most jurisdictions, and its regulatory status varies by country. Researchers continue to investigate its potential therapeutic applications, but it remains largely experimental at this stage.